Spyre Therapeutics Announces Grants of Inducement Awards

Spyre Therapeutics (NASDAQ: SYRE) announced inducement equity awards: stock options to purchase an aggregate of 46,600 shares granted to two non-executive employees under the 2018 Plan.

Rhea-AI Summary

Spyre Therapeutics (NASDAQ: SYRE) announced inducement equity awards: stock options to purchase an aggregate of 46,600 shares granted to two non-executive employees under the 2018 Plan. The grants were approved March 2, 2026 and comply with Nasdaq Listing Rule 5635(c)(4).

The options carry a 10-year term, an exercise price of $42.49 per share (closing price on March 2, 2026), and vest 25% after one year then monthly at 1/48th thereafter, subject to continuous service and plan terms.

Argus Mar 9 session

+2.29% close to close 1.1x rel. volume Open Argus

Details

News Market Reaction – SYRE

On Mar 9, the first trading day after this news, SYRE closed 2.29% above the previous close.

Data tracked by StockTitan Argus for the Mar 9 session.

Key Figures

Inducement options: 46,600 shares Option exercise price: $42.49 Option term: 10 years +5 more

Inducement options

46,600 shares

Aggregate stock options granted to two non-executive employees under 2018 Plan

Option exercise price

$42.49

Exercise price equal to SYRE Nasdaq closing price on March 2, 2026

Option term

10 years

Term of inducement stock options granted on March 2, 2026

Shelf capacity

$500,000,000

Maximum aggregate offering under Form S-3 base prospectus dated Feb 19, 2026

ATM program size

$154,059,875

Common stock under TD Cowen at-the-market sales agreement in S-3 prospectus

Cash & securities

$756.5 million

Cash, cash equivalents and marketable securities as of Dec 31, 2025

Q4 2025 net loss

$62.5 million

Quarterly net loss for Q4 2025 vs $56.3 million in 2024

Shares outstanding

78,540,164

Common shares outstanding as of Feb 12, 2026 (Form 10-K)

Historical Context

5 past events · Latest: Feb 24

5 events

1. Feb 24

   Conference participation

   24h Move

   +1.0%

   Management participation in three March 2026 healthcare investor conferences.

2. Feb 19

   Earnings and update

   24h Move

   +14.3%

   Q4 and 2025 results with strong cash runway and six 2026 readouts.

3. Feb 18

   Clinical data update

   24h Move

   +1.8%

   ECCO Congress data on SPY003 and dual TL1A/IL‑23 combination approach.

4. Feb 06

   Inducement awards

   24h Move

   -3.3%

   Inducement stock options totaling 30,200 shares for five employees.

5. Jan 23

   CCO inducement grant

   24h Move

   +0.8%

   Inducement option grant of 108,155 shares for new Chief Commercial Officer.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

inflammatory bowel disease, rheumatic diseases, equity inducement awards, Nasdaq Listing Rule 5635(c)(4)

4 terms

inflammatory bowel disease medical

"antibody combinations to redefine the standard of care for inflammatory bowel disease and rheumatic diseases"

Inflammatory bowel disease is a group of long‑lasting conditions that cause repeated inflammation of the digestive tract, leading to symptoms like belly pain, diarrhea, bleeding and weight loss. For investors it matters because IBD drives steady demand for medications, ongoing clinical trials, medical devices and diagnostics; think of it as a chronic maintenance market where successful treatments can create predictable, long‑term revenue streams and regulatory milestones can move stock prices.

rheumatic diseases medical

"standard of care for inflammatory bowel disease and rheumatic diseases"

Rheumatic diseases are a group of conditions that cause chronic inflammation, pain, stiffness, or damage in joints, muscles, and connective tissues—think of the body’s hinges and supporting ropes becoming swollen or worn. For investors, they matter because treatments, long-term care needs, and prevalence influence demand for drugs, medical devices, and services; successful therapies can change a company’s sales outlook much like a new engine changing a car’s performance.

equity inducement awards financial

"shares of common stock of Spyre to two non-executive employees as equity inducement awards under the Spyre Therapeutics, Inc. 2018 Equity Inducement Plan"

Equity inducement awards are special stock-based rewards given to new employees to encourage them to join a company or stay long-term. They are like signing bonuses paid with company shares instead of cash, helping motivate employees to contribute to the company's success.

Nasdaq Listing Rule 5635(c)(4) regulatory

"material to each employee's acceptance of employment with Spyre, in accordance with Nasdaq Listing Rule 5635(c)(4)"

NASDAQ Listing Rule 5635(c)(4) is a rule that requires a company to get approval from its shareholders before selling a large amount of its shares, usually over 20%. This helps protect investors by making sure the company doesn't flood the market with new shares without their say, which could lower the stock's value.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

WALTHAM, Mass., March 06, 2026 (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. (NASDAQ: SYRE) (the “Company” or “Spyre”), a clinical-stage biotechnology company pioneering long-acting antibodies and antibody combinations to redefine the standard of care for inflammatory bowel disease and rheumatic diseases, today announced that Spyre’s independent Compensation Committee of the Board of Directors approved the grant of stock options to purchase an aggregate of 46,600 shares of common stock of Spyre to two non-executive employees as equity inducement awards under the Spyre Therapeutics, Inc. 2018 Equity Inducement Plan, as amended (the “2018 Plan”). The stock options were approved on March 2, 2026 and were material to each employee's acceptance of employment with Spyre, in accordance with Nasdaq Listing Rule 5635(c)(4).

The stock options were granted with a 10-year term and an exercise price equal to $42.49, the closing price per share of Spyre's common stock as reported by Nasdaq on March 2, 2026. The options granted to the employees shall vest and become exercisable as to one-fourth (1/4th) of the shares subject to the respective options on the first anniversary of the employee’s start date, and one-forty-eighth (1/48th) of the shares subject to the respective options shall vest and become exercisable monthly thereafter, in each case, subject to continuous service with Spyre through the applicable vesting dates. The stock options are subject to the terms of the 2018 Plan.

About Spyre Therapeutics

Spyre Therapeutics is a clinical-stage biotechnology company pioneering long-acting antibodies and antibody combinations to redefine the standard of care for inflammatory bowel disease (“IBD”) and rheumatic diseases. Spyre's pipeline includes investigational extended half-life antibodies targeting α4β7, TL1A, and IL-23.

For more information, please visit http://spyre.com.

For Investors:
Eric McIntyre
SVP of Finance and Investor Relations
Spyre Therapeutics
Eric.mcintyre@spyre.com

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Spyre Therapeutics (SYRE) grant in the March 6, 2026 announcement?

Spyre granted stock options to purchase an aggregate of 46,600 shares to two non-executive employees. According to the company, the grants were approved March 2, 2026 and structured as inducement awards under the 2018 Plan.

What are the exercise price and term for the SYRE inducement stock options?

The options carry a $42.49 exercise price and a 10-year term. According to the company, $42.49 equals Spyre's Nasdaq closing price on March 2, 2026, the approval date of the grants.

How do the SYRE options vest for the newly hired employees?

Options vest 25% after the first anniversary, then 1/48th monthly thereafter. According to the company, vesting is subject to continuous service with Spyre through each applicable vesting date.

Why did Spyre issue these inducement awards under Nasdaq rules for SYRE?

The awards were approved as inducement grants that were material to each employee’s acceptance of employment. According to the company, the grants comply with Nasdaq Listing Rule 5635(c)(4) for new-hire inducement awards.

Are the SYRE stock options subject to any plan terms or conditions?

Yes, the options are subject to the terms of the Spyre Therapeutics 2018 Equity Inducement Plan, as amended. According to the company, exercise, vesting and other conditions follow the 2018 Plan provisions.